New drug trial targets rare, hard-to-treat stomach tumors
NCT ID NCT07434843
Summary
This study is testing whether the drug pemigatinib can help control advanced gastrointestinal stromal tumors (GIST) that have a specific genetic change (SDH-deficient). About 24 adults with this rare tumor type will take the drug as a daily pill for as long as it works and is tolerable. The main goal is to see if the drug shrinks tumors and to monitor its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.